Clinical Trial Update: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cemiplimab alone or in combination with fianlimab after stereotactic body radiotherapy in patients with clear cell renal cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: University of Oklahoma | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: RECRUITING